(NVO) Novo Nordisk - Overview

Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 161.915m USD | Total Return: -42.2% in 12m

Stock Diabetes Drugs, Obesity Drugs, Hormone Therapy, Blood Disorders
Total Rating 37
Safety 84
Buy Signal -0.83
Drug Manufacturers - General +6.3
Pharmaceuticals -0.1
Market Cap: 161,915m
Avg Trading Vol: 621M USD
ATR: 3.57%
Peers RS (IBD): 3.2
Risk 5d forecast
Volatility41.7%
Rel. Tail Risk-14.0%
Reward TTM
Sharpe Ratio-0.89
Alpha-61.08
Character TTM
Beta0.942
Beta Downside1.269
Drawdowns 3y
Max DD74.70%
CAGR/Max DD-0.28
EPS (Earnings per Share) EPS (Earnings per Share) of NVO over the last years for every Quarter: "2021-03": 0.44, "2021-06": 0.419, "2021-09": 0.42, "2021-12": 0.36, "2022-03": 0.47, "2022-06": 0.42, "2022-09": 0.43, "2022-12": 0.41, "2023-03": 0.63, "2023-06": 0.67, "2023-09": 0.73, "2023-12": 0.71, "2024-03": 0.83, "2024-06": 0.66, "2024-09": 6.12, "2024-12": 6.34, "2025-03": 6.53, "2025-06": 5.96, "2025-09": 4.5, "2025-12": 6.04, "2026-03": 0,
EPS CAGR: -40.10%
EPS Trend: 60.7%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of NVO over the last years for every Quarter: 2021-03: 33804, 2021-06: 33041, 2021-09: 35622, 2021-12: 38333, 2022-03: 42031, 2022-06: 41265, 2022-09: 45566, 2022-12: 48092, 2023-03: 53367, 2023-06: 54300, 2023-09: 58731, 2023-12: 65863, 2024-03: 65349, 2024-06: 68060, 2024-09: 71311, 2024-12: 85683, 2025-03: 78087, 2025-06: 76857, 2025-09: 74976, 2025-12: 78434.812, 2026-03: null,
Rev. CAGR: 18.10%
Rev. Trend: 95.2%
Last SUE: -0.15
Qual. Beats: 0
Risks
Technicals: volatile
Description: NVO Novo Nordisk

Novo Nordisk A/S (NVO) is a Danish pharmaceutical company. It researches, develops, manufactures, and distributes pharmaceutical products globally.

The company operates in two primary segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment addresses diabetes, obesity, cardiovascular, and other therapy areas. This segment is a significant part of the pharmaceutical sector, which focuses on chronic disease management. The Rare Disease segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. This segment often involves specialized and high-cost treatments.

Novo Nordisk also produces medical devices such as smart insulin pens (NovoPen 6, NovoPen Echo Plus) and an insulin dose guidance application (Dose Check), integrating technology with its pharmaceutical offerings. Its business model involves both drug development and the provision of supporting medical devices for patient care.

The company has a global presence, including Europe, North America, Asia, Latin America, the Middle East, and Africa. Consider exploring ValueRay for detailed financial metrics and competitive analysis.

Headlines to Watch Out For
  • Ozempic and Wegovy demand drives significant revenue growth
  • Increased competition in obesity drug market impacts market share
  • Regulatory approvals for new diabetes treatments expand product portfolio
  • Manufacturing capacity constraints limit GLP-1 drug supply
  • Healthcare policy changes affect drug pricing and reimbursement
Piotroski VR‑10 (Strict) 5.5
Net Income: 102.19b TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA -4.69 > 1.0
NWC/Revenue: -14.01% < 20% (prev -19.50%; Δ 5.49% < -1%)
CFO/TA 0.22 > 3% & CFO 119.10b > Net Income 102.19b
Net Debt (104.49b) to EBITDA (160.54b): 0.65 < 3
Current Ratio: 0.80 > 1.5 & < 3
Outstanding Shares: last quarter (4.45b) vs 12m ago -0.28% < -2%
Gross Margin: 80.98% > 18% (prev 0.85%; Δ 8.01k% > 0.5%)
Asset Turnover: 61.14% > 50% (prev 62.35%; Δ -1.21% > 0%)
Interest Coverage Ratio: 6.02 > 6 (EBITDA TTM 160.54b / Interest Expense TTM 23.78b)
Altman Z'' 3.14
A: -0.08 (Total Current Assets 172.45b - Total Current Liabilities 215.66b) / Total Assets 542.90b
B: 0.36 (Retained Earnings 195.30b / Total Assets 542.90b)
C: 0.28 (EBIT TTM 143.13b / Avg Total Assets 504.35b)
D: 0.56 (Book Value of Equity 194.05b / Total Liabilities 348.86b)
Altman-Z'' Score: 3.14 = A
Beneish M -3.14
DSRI: 0.82 (Receivables 75.70b/87.41b, Revenue 308.35b/290.40b)
GMI: 1.05 (GM 80.98% / 84.67%)
AQI: 0.98 (AQ_t 0.30 / AQ_t-1 0.31)
SGI: 1.06 (Revenue 308.35b / 290.40b)
TATA: -0.03 (NI 102.19b - CFO 119.10b) / TA 542.90b)
Beneish M-Score: -3.14 (Cap -4..+1) = AA
What is the price of NVO shares? As of April 04, 2026, the stock is trading at USD 36.75 with a total of 18,775,128 shares traded.
Over the past week, the price has changed by +6.37%, over one month by +4.57%, over three months by -30.44% and over the past year by -42.22%.
Is NVO a buy, sell or hold? Novo Nordisk has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold NVO.
  • StrongBuy: 4
  • Buy: 1
  • Hold: 5
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the NVO price?
Wallstreet Target Price 47.1 28.1%
Analysts Target Price 47.1 28.1%
NVO Fundamental Data Overview as of 03 April 2026
P/E Trailing = 10.2472
P/E Forward = 10.9051
P/S = 0.5239
P/B = 5.4413
P/EG = 4.8911
Revenue TTM = 308.35b USD
EBIT TTM = 143.13b USD
EBITDA TTM = 160.54b USD
Long Term Debt = 118.94b USD (from longTermDebt, last quarter)
Short Term Debt = 12.02b USD (from shortTermDebt, last quarter)
Debt = 130.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 104.49b USD (from netDebt column, last quarter)
Enterprise Value = 265.91b USD (161.91b + Debt 130.96b - CCE 26.96b)
Interest Coverage Ratio = 6.02 (Ebit TTM 143.13b / Interest Expense TTM 23.78b)
EV/FCF = 4.73x (Enterprise Value 265.91b / FCF TTM 56.18b)
FCF Yield = 21.13% (FCF TTM 56.18b / Enterprise Value 265.91b)
FCF Margin = 18.22% (FCF TTM 56.18b / Revenue TTM 308.35b)
Net Margin = 33.14% (Net Income TTM 102.19b / Revenue TTM 308.35b)
Gross Margin = 80.98% ((Revenue TTM 308.35b - Cost of Revenue TTM 58.65b) / Revenue TTM)
Gross Margin QoQ = 80.86% (prev 76.12%)
Tobins Q-Ratio = 0.49 (Enterprise Value 265.91b / Total Assets 542.90b)
Interest Expense / Debt = 6.59% (Interest Expense 8.63b / Debt 130.96b)
Taxrate = 21.34% (7.23b / 33.88b)
NOPAT = 112.59b (EBIT 143.13b * (1 - 21.34%))
Current Ratio = 0.80 (Total Current Assets 172.45b / Total Current Liabilities 215.66b)
Debt / Equity = 0.67 (Debt 130.96b / totalStockholderEquity, last quarter 194.05b)
Debt / EBITDA = 0.65 (Net Debt 104.49b / EBITDA 160.54b)
Debt / FCF = 1.86 (Net Debt 104.49b / FCF TTM 56.18b)
Total Stockholder Equity = 167.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.26% (Net Income 102.19b / Total Assets 542.90b)
RoE = 60.96% (Net Income TTM 102.19b / Total Stockholder Equity 167.64b)
RoCE = 49.94% (EBIT 143.13b / Capital Employed (Equity 167.64b + L.T.Debt 118.94b))
RoIC = 40.49% (NOPAT 112.59b / Invested Capital 278.04b)
WACC = 7.46% (E(161.91b)/V(292.87b) * Re(9.30%) + D(130.96b)/V(292.87b) * Rd(6.59%) * (1-Tc(0.21)))
Discount Rate = 9.30% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF] Terminal Value 80.46% ; FCFF base≈61.73b ; Y1≈61.48b ; Y5≈64.71b
[DCF] Fair Price = 354.3 (EV 1296.28b - Net Debt 104.49b = Equity 1191.79b / Shares 3.36b; r=7.46% [WACC]; 5y FCF grow -1.07% → 3.0% )
EPS Correlation: 60.68 | EPS CAGR: -40.10% | SUE: -4.0 | # QB: 0
Revenue Correlation: 95.21 | Revenue CAGR: 18.10% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.09 | Chg7d=-0.002 | Chg30d=-0.082 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=21.44 | Chg7d=+0.234 | Chg30d=+0.396 | Revisions Net=+2 | Growth EPS=-6.9% | Growth Revenue=-7.7%
EPS next Year (2027-12-31): EPS=22.05 | Chg7d=+0.168 | Chg30d=+0.230 | Revisions Net=-2 | Growth EPS=+1.8% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.5% (Discount Rate 9.3% - Earnings Yield 9.8%)
[Growth] Growth Spread = -6.1% (Analyst -6.5% - Implied -0.5%)
External Resources
Dataroma Stockcircle